| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.24 | 2e-11 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.27 | 2e-08 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.27 | 3e-08 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.18 | 8e-07 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.2 | 2e-06 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | 0.18 | 3e-06 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-05 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.2 | 3e-05 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.14 | 5e-05 |
| mRNA | AGK-2 | CTRPv2 | pan-cancer | AAC | 0.15 | 7e-05 |